INTRODUCTION
============

Topical antibiotics have been widely used in dermatologic postprocedural care[@B1]. Most dermatologic procedures create clean (class I) wounds, which are defined as the primary closure of wounds on clean, noncontaminated skin under sterile conditions[@B2]. The rates of wound infection after clean dermatologic procedures are generally very low, ranging from 0.07% to 4.25%[@B3],[@B4],[@B5],[@B6],[@B7],[@B8]. Controversy still exists about whether topical antibiotics have a prophylactic potential in patients undergoing clean dermatologic surgery[@B9]. Whereas some studies suggested that topical antibiotics can reduce the risk of infection[@B10],[@B11], other studies showed that prophylactic administration of topical antibiotics does not lower the surgical site infection rates in clean skin surgeries[@B12],[@B13],[@B14]. Indiscriminate use of topical antibiotics may contribute to the development of antibiotic resistance within the community and in the treated patients[@B15], and may cause allergic contact dermatitis[@B16],[@B17],[@B18]. Thus, the establishment of evidence-based, standard-of-care guidelines for the prophylactic use of topical antibiotics is necessary to avoid potential adverse events and to achieve satisfactory wound healing.

Previous investigations on the prophylactic use of topical antibiotics involved the use of topical antibiotics such as aminoglycosides (neomycin, gentamicin), polypeptides (bacitracin, polymyxin B), mupirocin, and chloramphenicol[@B10],[@B12],[@B13],[@B14],[@B19],[@B20]. Fusidic acid (sodium fusidate) is an antibiotic agent derived from the fungus *Fusidium coccineum* and is widely used in Korea. Although its coverage is limited to gram-positive bacteria such as *Staphylococcus aureus*, its allergic potential is less than that of neomycin or bacitracin[@B16],[@B18],[@B21]. The objective of this study is to compare the efficacy and safety between fusidic acid and petrolatum in the postprocedure management of clean dermatologic procedures.

MATERIALS AND METHODS
=====================

Patients and methods
--------------------

This retrospective study was conducted in an outpatient setting at the Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea. Between March 2012 and February 2013, all patients presenting with a skin lesion for which clean dermatologic procedures were deemed appropriate were considered eligible for the study. The types of dermatologic procedures included punch biopsy, incisional biopsy, excisional biopsy, and shave biopsy. Surgical procedures involving flaps or grafts were excluded. Each wound was classified into clean, clean-contaminated, contaminated, or infected wound according to the site and status of the wound based on the guideline for surgical wound stratification from the Centers for Disease Control and Prevention[@B2]. Patients with contaminated or dirty wound, traumatic wound, acute or nonpurulent inflammation, foreign body contamination, systemic infections, and use of systemic antibiotics were excluded, and only those with clean (class I) wound were enrolled in this study. Wounds in the axilla or perineal regions were excluded, and the locations treated were classified into seven regions: face and neck, trunk, buttock, arms, legs, hands, and foot. After the procedures, the patients were instructed to apply either fusidic acid ointment (Parason; SK Chemicals, Seongnam, Korea) or pure petrolatum (Vaseline; Unilever PLC, London, UK), leaving a thin covering over the entire wound area, once or twice a day for 1 to 2 weeks. The fusidic acid ointment contains 2% w/w (20 mg/g) of sodium fusidate as the active ingredient, and also includes cetanol, purified lanolin, concentrated glycerin, liquid paraffin, and white paraffin (petrolatum). Subjects with a known hypersensitivity to topical antibiotics were excluded. All procedures were performed in a sterile manner by using sterile gloves, drapes, and surgical sets. The study was approved by SMG-SNU Boramae Medical Center Institutional Review Board (IRB No. 26-2013-90) and conducted according to the ethical guidelines of the Declaration of Helsinki.

Outcome assessments
-------------------

The efficacy and safety were evaluated by using the retrieved medical records. On 7th or 14th days after the procedure, wounds were evaluated for efficacy including evidence of postprocedural infections and appropriate wound healing, as well as adverse events. More specifically, whereas the efficacy of a given agent was determined by evaluating wound discharge, pain, tenderness, swelling, induration, dehiscence, erythema, and general wound appearance, other application-related issues such as erythema, swelling, vesicle, itching, burning, and development of irritant or allergic contact dermatitis were considered as adverse events. Concurrently, each patient\'s level of satisfaction with the wound, in terms of healing status, cosmetic acceptability, and overall satisfaction, was evaluated at the clinic by using the following five-point scale: 5=very satisfied, 4=satisfied, 3=neutral/not sure, 2=dissatisfied, 1=very dissatisfied. The patients\' underlying medical conditions such as diabetes mellitus, malignancy, immunocompromised status, and other chronic consumptive diseases were also recorded.

Statistical analysis
--------------------

Data analysis was conducted on an intention-to-treat basis by using IBM SPSS Statistics 20.0 (IBM Co., Armonk, NY, USA). Student\'s t-test was used to compare continuous or ordinal variables. For categorical data, chi-square or Fisher\'s exact test was used as appropriate. *p*-values \<0.05 were considered statistically significant.

RESULTS
=======

A total of 414 consecutive patients (183 men and 231 women, mean age 47.5±22.0 years; range, 0\~95 years) with a total of 429 wounds undergoing clean dermatologic procedures were enrolled in this study. The patients\' skin types were either Fitzpatrick skin type III or IV. Fifteen patients had multiple wounds that were allocated to the identical treatment arm and assessed separately ([Table 1](#T1){ref-type="table"}). Whereas 203 subjects (213 wounds) applied fusidic acid, the remaining 211 subjects (216 wounds) used petrolatum for the postprocedure care. The number of wounds per subject, subject\'s age, and comorbidities were not significantly different between the two treatment groups.

The characteristics and outcomes of wounds are summarized in [Table 2](#T2){ref-type="table"}. In the fusidic acid and petrolatum groups, skin lesions from the face/neck (40.4% vs. 47.2%), trunk (20.2% vs. 24.1%), and legs (16.9% vs. 17.6%) were common, and the distribution of wound locations were not significantly different. Most wounds were created by punch biopsy (68.1% and 75.9% in the fusidic acid group and the petrolatum group, respectively), followed by excisional biopsy, shave biopsy, and incisional biopsy. The types of procedures were not significantly different between the two groups (*p*=0.186). The two groups showed a similar distribution of diagnoses: epidermal cyst, seborrheic keratosis, and actinic keratosis (in descending order).

In terms of efficacy, wounds from both groups underwent a similar wound healing process, and there was no wound discharge, pain, tenderness, swelling, induration, or dehiscence during follow-ups in both groups, indicating comparable efficacy between fusidic acid and petrolatum. The overall number of adverse events was 4 (0.9%), which is consistent with the reported incidence of adverse events associated with clean wounds after dermatologic procedures. The rate of adverse events in the fusidic acid group was 1.4% (three subjects), and that in the petrolatum group was 0.5% (1 subject); however, the difference was not significant (*p*=0.370). These three subjects treated with fusidic acid showed erythema (two patients) and itching (one patient). On the other hand, one subject treated with petrolatum developed only itching. The patients\' self-assessments of wound status were not significantly different between the treatment arms; most were satisfied with their wound (86.4% vs. 81.9%, fusidic acid group vs. petrolatum group). One fusidic acid-treated and one of two petrolatum-treated subjects who reported a dissatisfied rating experienced an itching sensation. The other subject treated with petrolatum complained that the overlying dressing easily fell off after petrolatum application.

DISCUSSION
==========

The current recommendations in wound management emphasize the need for a moist environment to facilitate optimal wound healing[@B22]. To this end, various topical emollients containing antibiotics have been used commonly in the belief that they may reduce the risk of infection and help in wound healing[@B23]. However, indiscriminate use of topical antibiotics has been associated with the increasing emergence of bacterial resistance[@B15] and the development of allergic contact dermatitis[@B16],[@B17],[@B18]. Accordingly, the use of neomycin and bacitracin, common culprits of allergic contact dermatitis, has been discouraged during the last decade.

For the first time in the literature, we report the use of fusidic acid, one of the most commonly used topical antibiotics in Korea and also a rare sensitizer that had exhibited a 0.3% patch test positivity in a contact dermatitis clinic[@B16] as a counterpart to pure petrolatum. Petrolatum, one of the vehicle ingredients of fusidic acid ointment, was used as a control treatment as previously described[@B12],[@B13],[@B14]. The rates of adverse events were 1.4% and 0.5% in the fusidic acid group and the petrolatum group, respectively. No significant differences were found in terms of adverse events and patient self-assessments of wound outcomes between the two treatment groups, corroborating previous landmark studies with bacitracin, gentamicin, and mupirocin[@B12],[@B13],[@B14].

Smack et al.[@B14] found no significant difference between postoperative wound infection rates between bacitracin and white petrolatum groups (0.9% and 2.0% in bacitracin and petrolatum group, respectively). Campbell et al.[@B13] also demonstrated no significant differences in infection rate in 147 second-intention wounds after Mohs micrographic auricular surgery between topical gentamicin and white petrolatum; however, gentamicin tended to more frequently produce inflammatory chondritis than petrolatum. Dixon et al.[@B12] compared the efficacy and safety associated with the postoperative use of topical mupirocin, sterile paraffin, and no ointment in 1,801 surgical wounds in 778 patients. There were no significant differences in outcomes for all endpoints, including infection rate, total complication rates, perception of wounds, postoperative pain, degree of inconvenience, and overall level of satisfaction. The mupirocin group showed significantly more cases of skin edge necrosis than the other groups[@B12]. Similarly, petrolatum-based ointment resulted in better wound outcomes than did antibiotic-containing treatments[@B24].

Topical antibiotics were the seventh most common source (2.5%) of non-North American Contact Dermatitis Group (NACDG) allergens between 2009 and 2010[@B17]. NACDG antigens such as neomycin and bacitracin still represent the second (8.7%) and fourth (8.3%) most common allergens, respectively, in North America during the same period[@B17]. Moreover, almost half of all anaphylactic reactions were attributed to topical antibiotics[@B25]. Erythema and pruritus observed in the fusidic acid group may be the symptoms of irritant or allergic contact dermatitis, which warrant further evaluations, including a patch test. Although there were a few case reports on allergic contact dermatitis implicating petrolatum as a cause[@B26],[@B27], the sensitizing risk of petrolatum appears minimal.

Another important concern about the postprocedure use of topical antibiotics is the possibility of an increase of antibiotic-resistant strains such as *S. aureus*, *S. epidermidis*, *Pseudomonas aeruginosa*, *Streptococcus pneumonia*, and *Propionibacterium acnes* in both patients and the community[@B1],[@B20]. Recent studies indicate a positive correlation between topical fusidic acid use and the subsequent isolation of fusidic acid-resistant *S. aureus*[@B28],[@B29],[@B30]. For example, in a UK study, a significant association was found between exposure to topical fusidic acid and resistance of an *S. aureus* isolate to fusidic acid (odds ratio, 2.77; 95% confidence interval, 1.01\~7.93)[@B28]. The development of resistance to fusidic acid may limit the efficacy of systemic fusidic acid for the treatment of serious staphylococcal infections[@B31]. On the other hand, like bacitracin, which eliminated Gram-positive organisms and promoted the growth of Gram-negative bacteria[@B14], fusidic acid has a potential to cause Gram-negative infection that may result in serious complications and treatment challenges.

This study has several limitations. The overall rate of adverse events was 0.9%, and this limited number of patients with adverse events led to underpowering of further analysis. Besides, a patch test was not performed to confirm the relation between fusidic acid and petrolatum concerning the observed adverse events such as erythema and itching sensation.

In conclusion, our findings suggest that the routine prophylactic use of topical antibiotics is not indicated for optimal wound healing and reduction of postoperative wound infection. Thus, we recommend the use of petrolatum in the postprocedure care of clean dermatologic procedures because its equivalent efficacy in infection rate and wound healing, excellent safety profiles, and cost-effectiveness.
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